Nu­va­lent joins the IPO par­ty less than 6 months af­ter launch, while Icosavax kicks its 'soc­cer bal­l' VLPs to Nas­daq

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Less than six months af­ter emerg­ing from stealth, the Deer­field-backed biotech Nu­va­lent is al­ready prep­ping a jump to Nas­daq. And it’s a leap that could prove high­ly prof­itable for the blue chip firm.

Nu­va­lent filed its S-1 pa­per­work Wednes­day, pen­cil­ing in the $100 mil­lion raise es­ti­mate that’s be­come com­mon­place dur­ing the IPO boom of the last 15 or so months. The fi­nal fig­ure may end up high­er giv­en the biotech’s crossover raise in May hit the $135 mil­lion mark, but even if it falls short, it’s a rapid as­cent for Nu­va­lent af­ter its Jan­u­ary de­but.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER